

Visualizing the Future

Advances in IL-23 Targeted Therapies in the Treatment of IBD

Sunday, May 19, 2024

6:30-8:00 PM ET

The Capital Hilton Hotel | Congressional/Senate | Dinner: 6:15 PM

CME OUTFITTERS 



Register Online
CMEOUTFITTERS.COM/IL23

ACTIVITY DESCRIPTION

Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mAbs) neutralize IL-23 by binding the Fab fragment to the P19 domain, the differences in Fc fragment structure may impact potency and clinical efficacy. Fc structure differences have been shown to impact binding of different agents to CD64-positive myelocytes, a main source of IL-23 in active IBD.

In this CME Outfitters symposium, expert faculty will review the role of the IL-23/Th-17 pathway in the pathogenesis of IBD and utilize animated 3-D models to illustrate differences in agents in the anti-IL-23 class that may have potential therapeutic implications. Learners will be guided through an evaluation of the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in IBD treatment, as well as the clinical evidence supporting the benefits of these IBD treatment features.

LEARNING OBJECTIVES

At the conclusion of this activity, learners will be able to better:

- Evaluate the role of various pro-inflammatory cytokines in driving inflammation in the pathogenesis of IBD
- Identify the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
- Assess the potential clinical implications of the ability of anti-IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23-producing cells

FACULTY

Miguel Regueiro, MD (Moderator)

Chief, Digestive Disease Institute
Professor in the Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Jessica R. Allegretti, MD, MPH, FACG, AGAF

Medical Director, Infusion Services
Director, Crohn's and Colitis Center
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, MA

Angelina E. Collins, MSN, ANP-BC

Board Certified Nurse Practitioner
Inflammatory Bowel Disease Center
UC San Diego Health
La Jolla, CA

Edward V. Loftus, Jr., MD

Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine and Science
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Mayo Graduate School of Medicine
Rochester, MN

This program is not affiliated with the Digestive Disease Week®.